Contact
Please use this form to send email to PR contact of this press release:
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
TO:
Please use this form to send email to PR contact of this press release:
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
TO: